ARCHIVES

Phase III Xtandi Trial Meets Primary Endpoints Of Progression-Free and Overall Survival

This article is from The Cancer Letter archive.

Vol. 36 No. 11 | November 29, 2013

Download PDF Visit The Full Archive

Related Articles

Tivozanib Does Not Improve OS Compared to Sorafenib

February 22, 2013

NTP Committee Finds Five Test Reports Show “Limited” Evidence Of Carcinogenicity

February 27, 1981

House subcommittee’s 5.6% Increase For NIH includes $2.5 Billion for NCI

July 18, 1997

SWOG Releases RFA For Use Of Biorepository

November 12, 2010

Klausner Unveils New NCI Structure, Aims To Change Institute’s “Ethos”

August 11, 1995

In Brief: House Hearings On NIH Budget Begin Feb. 1; Army Program Is Peer Reviewing Proposals

January 28, 1994